Lundbeck Expands Azilect Marketing Agreement With Teva In Asia

The agreement comes on top of the recent grant of reimbursement in China on two of Lundbeck’s key products Cipralex and Ebixa.

As part of the agreement Lundbeck will be responsible for conducting the clinical trials and preparing the application filings needed to gain a marketing authorisation in the individual markets. The first launch in one of the markets may potentially occur in approximately one year.

Ole Chrintz, senior vice president of commercial operations at Lundbeck, said: “With the new agreement with our partner Teva, we get an opportunity to expand our already successful work with Azilect. The pharmaceutical markets in Asia, and the CNS market in particular, is undergoing rapid development, and we see this agreement as a possibility to further strengthen our commercial platform in this promising region.

“Azilect is an important treatment option in an unsatisfied Parkinson’s disease market and is the first medication that in clinical trials has shown an effect consistent with the possibility of disease modification in parkinson’s disease. We are glad that we will now be able to offer this effective treatment to the population in the Asian countries.”

Specific financial terms remain undisclosed but Lundbeck will pay a share of net sales in the markets to Teva.